Related content

Suramin treatment in hormone- and chemotherapy-refractory prostate cancer - anti-androgen treated patients

By Garcia-Schurmann J.M.   Schulze H.   Haupt G.   Pastor J.   Allolio B.   Senge T.  

Urology, Vol. 53, Iss. 3, 1999-03 ,pp. : 535-541

Elsevier

Access to resources Recommend Favorite

Hormone-refractory Prostate Cancer? Anti-androgen Withdrawal and Intermittent Hormone Therapy

By Sciarra Alessandro   Casale Paolo   Colella Dario   Chiro Costantino Di   Silverio Franco Di  

Scandinavian Journal of Urology and Nephrology, Vol. 33, Iss. 4, 1999-09 ,pp. : 211-216

Informa Healthcare

Access to resources Recommend Favorite

Antiandrogen withdrawal syndrome in prostate cancer after treatment with steroidal antiandrogen chlormadinone acetate

By Akakura K.   Akimoto S.   Ohki T.   Shimazaki J.  

Urology, Vol. 45, Iss. 4, 1995-04 ,pp. : 700-705

Elsevier

Access to resources Recommend Favorite

Androgen independent progression in prostate cancer: Risk factors

By Auzanneau C.   Irani J.   Dahmani L.   Ouaki F.   Pires C.   Dore B.  

European Urology Supplements, Vol. 2, Iss. 1, 2003-02 ,pp. : 26-26

Elsevier

Access to resources Recommend Favorite

Combined androgen blockade for the treatment of metastatic cancer of the prostate

By Schellhammer P.F.  

Urology, Vol. 47, Iss. 5, 1996-05 ,pp. : 622-628

Elsevier

Access to resources Recommend Favorite